We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Tests Available for Multiple STIs

By LabMedica International staff writers
Posted on 31 Jul 2018
Mycoplasma genitalium (MG) is a sexually transmitted, small and pathogenic bacterium that lives on the ciliated epithelial cells of the urinary and genital tracts in humans. More...
It is spread through unprotected intercourse and is now becoming resistant to antibiotics.

MG can present similar symptoms to chlamydia, which is the most common sexually transmitted infections (STI) in Australia, including a burning sensation when urinating and pain or bleeding during and after intercourse. Males may experience watery discharge from their penis. However, many patients are asymptomatic and do not know they are infected.

Most laboratories routinely test for chlamydia and gonorrhea, the two most pathogenic STIs, however Mycoplasma, Trichomonas and Ureaplasma are also STI infections, which can have health implications. AusDiagnostics (Mascot, Australia) a leading commercial supplier of highly multiplexed diagnostics to microbiology laboratories, currently sells a molecular test kit for all five STIs and is adding the common resistance genes found in Mycoplasma and gonorrhea in a new kit being validated at a hospital in Melbourne.

In a study performed at the hospital in Australia, samples that had previously been analyzed for chlamydia and gonorrhea were re-analyzed on the AusDiagnostics test kit. Three out of 72 were found to contain Mycoplasma genitalium and seven contained Ureaplasma urealyticum. This means that the traditional testing missed 14% of the STIs. Although the jury is still out on the severity of Ureaplasma in STI infections, this is still useful information for the treating doctor. In another study, four Trichomonas positives were found in 200 samples that had previously been declared free of STIs using tests that only measured chlamydia and gonorrhea.

Keith Stanley PhD, a professor and AusDiagnostics Managing Director, said, “It is important for doctors to test for a range of STIs to ensure that patients are treated for infections as early as possible. The advantage of a multiplex approach is that all the STI organisms and their resistance can be measured at one time from one sample instead of having to request a second test for resistance once a positive is found. This simplifies the laboratory work flow and reduces the chance of missing an important infection.”

Related Links:
AusDiagnostics


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Repetitive Pipette
VWR® Stepper Pro
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.